Khan mosin s (61 risultati)

Condizione: New.

Paperback. Condizione: Brand New. 196 pages. 8.66x5.91x0.45 inches. In Stock.

Taschenbuch. Condizione: Neu. Genetic Alterations in Thyroid Cancer Patients of Kashmir Valley | Race against Thyroid Cancer | Mosin S. Khan (u. a.) | Taschenbuch | 196 S. | Englisch | 2016 | LAP LAMBERT Academic Publishing | EAN 9783659954924 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu. …

paperback. Condizione: New. NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Condizione: New.

Condizione: New.

Condizione: New.

Condizione: New.

Taschenbuch. Condizione: Neu. Altérations génétiques chez les patients atteints de cancer de la thyroïde dans la vallée du Cachemire | La course contre le cancer de la thyroïde | Mosin S. Khan (u. a.) | Taschenbuch | Französisch | 2025 | Editions Notre Savoir | EAN 9786208921958 | Verantwortliche Person für die EU: SIA OmniScriptum Publishing, Brivibas Gatve 197, 1039 RIGA, LETTLAND, customerservice[at]vdm-vsg[dot]de | Anbieter: preigu.…

Condizione: New.

Condizione: New.

Taschenbuch. Condizione: Neu. Alterações genéticas em pacientes com cancro da tiróide do Vale da Caxemira | Corrida contra o cancro da tiróide | Mosin S. Khan (u. a.) | Taschenbuch | Portugiesisch | 2025 | Edições Nosso Conhecimento | EAN 9786208922009 | Verantwortliche Person für die EU: SIA OmniScriptum Publishing, Brivibas Gatve 197, 1039 RIGA, LETTLAND, customerservice[at]vdm-vsg[dot]de | Anbieter: preigu.…

Condizione: New.

Condizione: New.

Condizione: New.

Taschenbuch. Condizione: Neu. Genetische Veränderungen bei Schilddrüsenkrebspatienten im Kaschmirtal | Wettlauf gegen Schilddrüsenkrebs | Mosin S. Khan (u. a.) | Taschenbuch | 200 S. | Deutsch | 2025 | Verlag Unser Wissen | EAN 9786208921941 | Verantwortliche Person für die EU: SIA OmniScriptum Publishing, Brivibas Gatve 197, 1039 RIGA, LETTLAND, customerservice[at]vdm-vsg[dot]de | Anbieter: preigu.…

Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Thyroid carcinoma is the most prevalent endocrine malignancy and accounts for 2% of all human cancers. We screened exon 15 of BRAF gene; exons 1 and 2 of RAS genes in sixty (60) consecutive thyroid tissue (tumor and adjacent normal) samples. Overall mutations in BRAF was found to be 25% (15 of 60) affecting codon 600 (valine to glutamine) and restricted only to papillary thyroid cancer but devoid of any RAS mutation. We screened 140 blood samples from thyroid cancer patients for HRAS T81C and RET polymorphism in comparison with 170 cancer-free controls. TSHR gene was found to be hyper methylated in 25 % (15 of 60) of the cases with strong association with elevated TSH levels. We conclude that both mutational events as well as over-expression of BRAF gene is highly implicated in pathogenesis of thyroid cancer and the BRAF protein overexpression is independent of the BRAF mutational status. HRAS T81C and RET polymorphisms moderately increases thyroid cancer risk. Our study showed a high implication of TSHR gene methylation and its signi cant association with BRAF V600E mutation in thyroid tumors, depicting a positive connection between TSHR pathway and MAP Kinase pathway. 196 pp. Englisch.…

Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Khan Mosin S.Dr. Mosin Saleem Khan (born, 17.11.1985) was conferred Ph.D (Biochemistry and Molecular biology) from Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Soura, Srinagar. Dr. Mosin is the recipient of University Gold M. …

PAP. Condizione: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

Taschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Thyroid carcinoma is the most prevalent endocrine malignancy and accounts for 2% of all human cancers. We screened exon 15 of BRAF gene; exons 1 and 2 of RAS genes in sixty (60) consecutive thyroid tissue (tumor and adjacent normal) samples. Overall mutations in BRAF was found to be 25% (15 of 60) affecting codon 600 (valine to glutamine) and restricted only to papillary thyroid cancer but devoid of any RAS mutation. We screened 140 blood samples from thyroid cancer patients for HRAS T81C and RET polymorphism in comparison with 170 cancer-free controls. TSHR gene was found to be hyper methylated in 25 % (15 of 60) of the cases with strong association with elevated TSH levels. We conclude that both mutational events as well as over-expression of BRAF gene is highly implicated in pathogenesis of thyroid cancer and the BRAF protein overexpression is independent of the BRAF mutational status. HRAS T81C and RET polymorphisms moderately increases thyroid cancer risk. Our study showed a high implication of TSHR gene methylation and its signi cant association with BRAF V600E mutation in thyroid tumors, depicting a positive connection between TSHR pathway and MAP Kinase pathway.…

PAP. Condizione: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware 196 pp. Spanisch.

Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Thyroid carcinoma is the most prevalent endocrine malignancy and accounts for 2% of all human cancers. We screened exon 15 of BRAF gene; exons 1 and 2 of RAS genes in sixty (60) consecutive thyroid tissue (tumor and adjacent normal) samples. Overall mutations in BRAF was found to be 25% (15 of 60)affecting codon 600 (valine to glutamine) and restricted only to papillary thyroid cancer but devoid of any RAS mutation. We screened 140 blood samples from thyroid cancer patients for HRAS T81C and RET polymorphism in comparison with 170 cancer-free controls. TSHR gene was found to be hyper methylated in 25 % (15 of 60) of the cases with strong association with elevated TSH levels. We conclude that both mutational events as well as over-expression of BRAF gene is highly implicated in pathogenesis of thyroid cancer and the BRAF protein overexpression is independent of the BRAF mutational status. HRAS T81C and RET polymorphisms moderately increases thyroid cancer risk. Our study showed a high implication of TSHR gene methylation and its signi¿cant association with BRAF V600E mutation in thyroid tumors, depicting a positive connection between TSHR pathway and MAP Kinase pathway.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 196 pp. Englisch.…

Taschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - El carcinoma de tiroides es la neoplasia endocrina más prevalente y representa el 2% de todos los cánceres humanos. Hemos analizado el exón 15 del gen BRAF y los exones 1 y 2 de los genes RAS en sesenta (60) muestras consecutivas de tejido tiroideo (tumoral y normal adyacente). Se encontró que las mutaciones globales en BRAF eran del 25% (15 de 60) y afectaban al codón 600 (de valina a glutamina) y estaban restringidas únicamente al cáncer papilar de tiroides, pero carecían de cualquier mutación en RAS. Se analizaron 140 muestras de sangre de pacientes con cáncer de tiroides para detectar el polimorfismo HRAS T81C y RET en comparación con 170 controles libres de cáncer. Se encontró que el gen TSHR estaba hipermetilado en el 25% (15 de 60) de los casos con una fuerte asociación con niveles elevados de TSH. Concluimos que tanto los eventos mutacionales como la sobreexpresión del gen BRAF están altamente implicados en la patogénesis del cáncer de tiroides y que la sobreexpresión de la proteína BRAF es independiente del estado mutacional de BRAF. Los polimorfismos HRAS T81C y RET aumentan moderadamente el riesgo de cáncer de tiroides. Nuestro estudio mostró una alta implicación de la metilación del gen TSHR y su asociación signi¿cativa con la mutación BRAF V600E en tumores de tiroides, lo que representa una conexión positiva entre la vía TSHR y la vía MAP Kinasa.…

Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Le carcinome thyroïdien est la tumeur maligne endocrinienne la plus répandue et représente 2 % de tous les cancers humains. Nous avons analysé l'exon 15 du gène BRAF et les exons 1 et 2 des gènes RAS dans soixante (60) échantillons consécutifs de tissu thyroïdien (tumeur et tissus normaux adjacents). Les mutations globales de BRAF se sont révélées être 25% (15 sur 60) affectant le codon 600 (valine à glutamine) et limitées uniquement au cancer papillaire de la thyroïde, mais dépourvues de toute mutation de RAS. Nous avons analysé 140 échantillons de sang de patients atteints de cancer de la thyroïde à la recherche du polymorphisme HRAS T81C et RET, en comparaison avec 170 témoins exempts de cancer. Le gène TSHR s'est révélé hyperméthylé dans 25 % (15 sur 60) des cas, avec une forte association avec des niveaux élevés de TSH. Nous concluons que les événements mutationnels ainsi que la surexpression du gène BRAF sont fortement impliqués dans la pathogenèse du cancer de la thyroïde et que la surexpression de la protéine BRAF est indépendante du statut mutationnel de BRAF. Les polymorphismes HRAS T81C et RET augmentent modérément le risque de cancer de la thyroïde. Notre étude a montré une forte implication de la méthylation du gène TSHR et son association significative avec la mutation BRAF V600E dans les tumeurs thyroïdiennes, décrivant une connexion positive entre la voie TSHR et la voie MAP Kinase. 200 pp. Französisch.…

Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -El carcinoma de tiroides es la neoplasia endocrina más prevalente y representa el 2% de todos los cánceres humanos. Hemos analizado el exón 15 del gen BRAF y los exones 1 y 2 de los genes RAS en sesenta (60) muestras consecutivas de tejido tiroideo (tumoral y normal adyacente). Se encontró que las mutaciones globales en BRAF eran del 25% (15 de 60) y afectaban al codón 600 (de valina a glutamina) y estaban restringidas únicamente al cáncer papilar de tiroides, pero carecían de cualquier mutación en RAS. Se analizaron 140 muestras de sangre de pacientes con cáncer de tiroides para detectar el polimorfismo HRAS T81C y RET en comparación con 170 controles libres de cáncer. Se encontró que el gen TSHR estaba hipermetilado en el 25% (15 de 60) de los casos con una fuerte asociación con niveles elevados de TSH. Concluimos que tanto los eventos mutacionales como la sobreexpresión del gen BRAF están altamente implicados en la patogénesis del cáncer de tiroides y que la sobreexpresión de la proteína BRAF es independiente del estado mutacional de BRAF. Los polimorfismos HRAS T81C y RET aumentan moderadamente el riesgo de cáncer de tiroides. Nuestro estudio mostró una alta implicación de la metilación del gen TSHR y su asociación signi¿cativa con la mutación BRAF V600E en tumores de tiroides, lo que representa una conexión positiva entre la vía TSHR y la vía MAP Kinasa.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 196 pp. Spanisch.…

Taschenbuch. Condizione: Neu. Alteraciones genéticas en pacientes con cáncer de tiroides del valle de Cachemira | Carrera contra el cáncer de tiroides | Mosin S. Khan (u. a.) | Taschenbuch | Spanisch | 2025 | Ediciones Nuestro Conocimiento | EAN 9786208921989 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu Print on Demand. …

PAP. Condizione: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

PAP. Condizione: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

PAP. Condizione: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.